X Says it Will Resist ‘Politically Motivated' French Probe
Why the Federal Reserve's Building Renovation Costs $2.5 Billion
Milan Corruption Probe Casts Shadow Over Property Boom
How San Jose's Mayor Is Working to Build an AI Capital
'X remains in the dark as to the specific allegations made against the platform,' the company said in a post on its Global Government Affairs handle on Monday. 'X believes that this investigation is distorting French law in order to serve a political agenda and, ultimately, restrict free speech.'
Earlier in July, Paris prosecutors opened an investigation into suspected interference and fraudulent data extraction from 'an automatic data-processing system.' The probe follows two reports from lawmaker Eric Bothorel and a high-level official at a French public institution alleging X's algorithm was being used for foreign interference.
X denies the allegations and said the probe stemmed from biased experts who have previously been involved in campaigns dedicated to getting users to quit X or 'demonstrate open hostility towards X.'
'The involvement of these individuals raises serious concerns about the impartiality, fairness, and political motivations of the investigation, to put it charitably. A predetermined outcome is not a fair one,' X said in the post.
The company is also being investigated by the European Union over compliance with the bloc's Digital Services Act, which requires platforms to tackle illegal content and disinformation and follow transparency rules. The EU is leading a global crackdown on harmful online content and disinformation that's sparked increasingly vocal responses from Musk, who has said such measures restrict free speech.
--With assistance from Gaspard Sebag.
A Rebel Army Is Building a Rare-Earth Empire on China's Border
Elon Musk's Empire Is Creaking Under the Strain of Elon Musk
Thailand's Changing Cannabis Rules Leave Farmers in a Tough Spot
How Starbucks' CEO Plans to Tame the Rush-Hour Free-for-All
What the Tough Job Market for New College Grads Says About the Economy
©2025 Bloomberg L.P.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
LeBron James, Nikola Jokić reportedly meet over $5bn upstart to rival NBA
A high-profile meeting last week in France between LeBron James, his business partner Maverick Carter and Nikola Jokić's agent Miško Ražnatović was about plans for a new $5bn international basketball league, according to a report by Front Office Sports, which cited multiple sources familiar with the matter. The proposed league, spearheaded by Carter, would feature six men's and six women's teams that travel together to eight global cities in a touring format. Inspired by LIV Golf and Formula One, the league aims to offer players equity stakes, something NBA rules currently prohibit for active athletes. Ražnatović, a powerful figure in European basketball, posted a photo of the meeting on Instagram over the weekend. The caption, tagged in Saint-Tropez, teased: 'The summer of 2025 is the perfect time to make big plans for the fall of 2026.' That photo fueled speculation about a potential team-up between James and Jokić, but sources confirmed to Front Office Sports the meeting was unrelated to the NBA. Carter began pitching the league earlier this year, with Bloomberg reporting in January that he is seeking to raise $5bn in funding. Backers already include the Singapore government, Saudi Arabia's Public Investment Fund, SC Holdings, UBS and investors such as Skype co-founder Geoff Prentice and former Facebook executive Grady Burnett. Unlike the WNBA-adjacent Unrivaled league, which allows dual participation, Carter's venture is expected to require full-time commitments, effectively ruling out NBA participation unless league rules change. The NBA, meanwhile, is pursuing its own expansion into Europe. Commissioner Adam Silver and deputy commissioner Mark Tatum met with UK prime minister Keir Starmer in London last week to discuss plans for a Europe-based NBA league in partnership with Fiba. As part of that effort, the NBA announced that the Orlando Magic and Memphis Grizzlies will play regular-season games in Berlin and London in January 2026. EuroLeague officials have pushed back against the NBA's expansion talks. 'We said to them, like we said publicly, we don't believe that the new league is something that would help the market,' EuroLeague CEO Paulius Motiejūnas told the Athletic on Tuesday.
Skift
27 minutes ago
- Skift
Don't Count Out Google Travel Search
The long-term attractiveness of Google Search is still an open question. That's why Booking and others are looking to diversify. Think AI will kill Google travel search? It hasn't happened yet. Booking Holdings Chief Financial Officer Ewout Steenbergen said the company's ads in Google continue to perform — even as Booking diversifies its favored marketing platforms. "Google clicks continue to hold up quite well," Steenbergen told analysts earlier this week during Booking's second quarter earnings call. He said clicks are growing when Booking places ads in Google for its core accommodations business. "So we don't see a decline in that yet," he said. Google's Search Business Is Growing, Not
Yahoo
an hour ago
- Yahoo
Ascendis Pharma to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025
COPENHAGEN, Denmark, July 31, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2025 financial results and provide a business update on Thursday, August 7, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on August 7, 2025, at 4:30 p.m. Eastern Time (ET) to discuss its second quarter 2025 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after the conclusion of the event for 30 days. About Ascendis Pharma A/S Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit to learn more. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis' ability to apply its TransCon technology platform to make a meaningful difference for patients and (ii) Ascendis' application of TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 12, 2025, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law. Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo and TransCon are trademarks owned by the Ascendis Pharma group. © July 2025 Ascendis Pharma A/S. Investor Contacts: Media Contact: Sarada Weerasinghe Melinda Baker Ascendis Pharma Ascendis Pharma ir@ media@ Patti Bank ICR Healthcare +1 (415) 513-1284
